◆英語タイトル:Solid Biosciences Inc (SLDB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8151
◆発行会社(調査会社):
GlobalData
◆発行日:2018年10月
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Solid Biosciences Inc (Solid Biosciences) is a life science company focused on developing therapies for duchenne muscular dystrophy (DMD). Its pipeline product candidates include SGT-001, a microdystrophin gene therapy administered through adeno-associated virus (AAV) stabilizes dystrophin glycoprotein complex and rescue muscle function; SB-001, a monoclonal antibody to reduce fibrosis and inflammation in DMD patients. Solid Biosciences has development programs across four scientific platforms which include corrective therapies, disease-modifying therapies, disease understanding and assistive devices. The company works in collaboration with University of Massachusetts Medical School, The Duchenne Research Fund, University of Washington, Alex’s Wish, and others. Solid Biosciences is headquartered in Cambridge, Massachusetts, the US.
Solid Biosciences Inc (SLDB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Solid Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Solid Biosciences Raises USD50 Million in Series C Financing 10
Solid GT Raises USD42.5 Million in Series B Financing Round 12
Partnerships 13
Synpromics Enters into Research Partnership with Solid Biosciences 13
Solid Biosciences Enters into Agreement with University of Washington 14
Solid Biosciences Enters into Agreement with Strykagen 15
Solid Biosciences Enters into Co-Development Agreement with Northwestern University 16
Debiopharm Enters into Agreement with Solid Biosciences 17
Licensing Agreements 18
Solid Biosciences Enters into Licensing Agreement with Biotech Company 18
Solid Biosciences Enters into Licensing Agreement with University of Michigan 19
Solid GT Enters into Licensing Agreement with University of Missouri 20
Equity Offering 21
Solid Biosciences Raises USD143.8 Million in IPO of Shares 21
Solid Biosciences Inc – Key Competitors 23
Solid Biosciences Inc – Key Employees 24
Solid Biosciences Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Aug 10, 2018: Solid Biosciences Reports Second Quarter 2018 Financial Results and Provides Business Update 26
May 10, 2018: Solid Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update 28
Mar 29, 2018: Solid Biosciences Reports Full Year 2017 Financial Results and Provides Corporate Update 30
Corporate Communications 32
Sep 13, 2018: Solid Biosciences welcomes Sukumar Nagendran, M.D., to its board Of directors 32
Jun 26, 2018: Solid Biosciences Names Dr. Martin Freed As Board Director 33
Jun 07, 2017: Solid Biosciences Strengthens Leadership Team to Advance Programs for Duchenne Muscular Dystrophy 34
Clinical Trials 35
May 11, 2017: New Preclinical Data Support SGT-001 As A Novel Treatment Approach For Duchenne Muscular Dystrophy 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36
List of Tables
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Solid Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Solid Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Solid Biosciences Raises USD50 Million in Series C Financing 10
Solid GT Raises USD42.5 Million in Series B Financing Round 12
Synpromics Enters into Research Partnership with Solid Biosciences 13
Solid Biosciences Enters into Agreement with University of Washington 14
Solid Biosciences Enters into Agreement with Strykagen 15
Solid Biosciences Enters into Co-Development Agreement with Northwestern University 16
Debiopharm Enters into Agreement with Solid Biosciences 17
Solid Biosciences Enters into Licensing Agreement with Biotech Company 18
Solid Biosciences Enters into Licensing Agreement with University of Michigan 19
Solid GT Enters into Licensing Agreement with University of Missouri 20
Solid Biosciences Raises USD143.8 Million in IPO of Shares 21
Solid Biosciences Inc, Key Competitors 23
Solid Biosciences Inc, Key Employees 24
Solid Biosciences Inc, Subsidiaries 25
List of Figures
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Solid Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8